The main characteristics of the active ingredients of the FLU-M® vaccine and the indicator of its quality consist of its ability to develop an efficient immune response against the strains that circulate in the world in the current epidemiological season.

The technological production process guarantees optimal conditions adapted to:

• Support the components that intervene in the necessary defense to guarantee the effective interaction "antigen-antibody" and preserve the so-called "epitopes that intervene in the defense".
• Manufacture pharmaceutical products that meet all international requirements.

Hemagglutinin is the main protective antigen which is an integral membrane protein with a tendency to aggregation. The composition of the FLU-M® vaccine includes a stabilizer that prevents hemagglutinin aggregation and the loss of its antigenic properties..

The FLU-M® vaccine is produced using highly purified antigens of low reactogenicity.

Its immunobiological activity properties meet international requirements for influenza vaccines and guarantee the development of immunity against influenza after its application.

The technological production process guarantees optimal conditions adapted to:

• Support the components that intervene in the necessary defense to guarantee the effective interaction "antigen-antibody" and preserve the so-called "epitopes that intervene in the defense".
• Manufacture pharmaceutical products that meet all international requirements.

Hemagglutinin is the main protective antigen which is an integral membrane protein with a tendency to aggregation.

Influenza Vaccine (split virion, inactivated) has a relatively low degree of side effects, its immunobiological activity properties meet international requirements for influenza vaccines and ensure the development of immunity against influenza after its application.

QUALITATIVE AND QUANTITATIVE COMPOSITION
FLU-M® Tetra is a mixture of highly purified surface protective antigens and internal influenza virus antigens, equivalent to subtypes A (H1N1, H3N2) and type B (Yamagata and Victoria lineages), in phosphate buffered saline. Influenza viruses are grown in chicken embryos and inactivated with betapropiolactone.

The antigenic composition of the vaccine is modified every year according to the WHO recommendations for the northern and southern hemispheres of the current epidemiological season.

Indications
Convacell® is indicated for the prevention of infection caused by the coronavirus (COVID-19) in adults aged 18 years and older.

Vaccination is particularly recommended for:

• Individuals over 18 years of age who have neither contracted nor previously been vaccinated against SARS-CoV-2 infection.
• Individuals over 60 years of age.
• Individuals with chronic diseases, including bronchopulmonary diseases, tuberculosis, cardiovascular diseases, diabetes mellitus, and obesity.
• Individuals with primary or secondary immunodeficiencies, including HIV, autoimmune diseases, and oncological/oncohematological conditions.

Revaccination against SARS-CoV-2 infection should be administered no earlier than 1 year after the previous vaccination.

Composition
Convacell® consists of a recombinant nucleocapsid protein of the SARS-CoV-2 virus, produced in Escherichia coli, and a mixture of excipients in the form of an emulsion.

It is important to note that this vaccine does not protect against infections caused by S. pneumoniae serotypes not included in the formulation, nor is it indicated for the treatment of active infections at the time of vaccination.

The vaccine is indicated for infants and children from 6 weeks to 5 years of age, for the prevention of invasive diseases caused by the 13 S. pneumoniae serotypes.